The paper: https://doi.org/10.1038/s41591-018-0092-9 https://doi.org/10.1038/s41591-018-0092-9 The usual sources for bypassing journal paywalls will work. The

The paper: https://doi.org/10.1038/s41591-018-0092-9 https://doi.org/10.1038/s41591-018-0092-9 The usual sources for bypassing journal paywalls will work. The lifespan curves in the paper are very nice: same slope, shifted to the right all the way down to 100% cohort mortality. The 36% increase in remaining life span refers to the difference between 140 days and 190 days to 50% cohort mortality in the control and treated group respectively. Senolytic approaches that clear some fraction of senescent cells are highly reliable when it comes to extending life span and reversing aspects of aging in mice. The drug combination used here, dasatinib and quercetin, is cheap: $100-200/dose if you are shopping carefully. It is being trialed by the non-profit Betterhumans at the moment in a 65+ year old human group. Dasatinib is a generic, so there is absolutely zero interest in anyone taking this into a development program, which is a shame. None of the later pharmaceuticals have yet demonstrated any better results in terms of percentage of senescent cells killed off, but FOXO4-DRI has essentially no side effects. (If you are interested, dasatinib pharmacokinetics and side-effects are pretty well described. E.g. https://doi.org/10.1124/dmd.107.018267 https://doi.org/10.1124/dmd.107.018267 ) Based on reporting from the self-experimentation community, and first principles arguments, senolytics are something to take once every few years, and don't expect to see noteworthy effects unless you are into high cancer risk years or have something like obesity or early arthritis going on, in which more than the usual count of senescent cells will be in place. Senescent cell contribution to aging most likely scales in the same way as cancer risk and for the same reason, loss of immunosurveillance. Or you could wait for the human trial results to be published. Those will start to emerge next year for various senolytic candidates. An interesting thought: compelling evidence for senescent cells to be an important contribution to aging has existed for 30+ years. The research community deliberately avoided engagement with treatment of aging as a medical condition from the 1970s to a decade or so ago. It took a lot of advocacy and people coming in from outside the research community to make that change. If that cultural black hole for development had not happened, how much sooner could simple pharmaceuticals have been discovered that significantly addressed aspects of aging in humans through selective destruction of senescent cells? Another thought: there has been the usual foaming at the mouth over the past decade among those who decry rejuvenation therapies as the purview of the ultra-wealthy. Dasatinib and quercetin at $100-200/dose, at one dose every two years or so? That is much closer to the future of longevity science that this wild tale of massively expensive approaches hoarded by the rich.